"HIV Protease Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly.
| Descriptor ID |
D017320
|
| MeSH Number(s) |
D27.505.519.389.745.420 D27.505.954.122.388.077.088.420
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "HIV Protease Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "HIV Protease Inhibitors".
This graph shows the total number of publications written about "HIV Protease Inhibitors" by people in this website by year, and whether "HIV Protease Inhibitors" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 4 | 0 | 4 |
| 1995 | 1 | 2 | 3 |
| 1996 | 3 | 0 | 3 |
| 1997 | 7 | 5 | 12 |
| 1998 | 13 | 7 | 20 |
| 1999 | 17 | 5 | 22 |
| 2000 | 16 | 6 | 22 |
| 2001 | 17 | 5 | 22 |
| 2002 | 22 | 11 | 33 |
| 2003 | 12 | 9 | 21 |
| 2004 | 13 | 12 | 25 |
| 2005 | 12 | 4 | 16 |
| 2006 | 14 | 8 | 22 |
| 2007 | 23 | 16 | 39 |
| 2008 | 18 | 12 | 30 |
| 2009 | 19 | 9 | 28 |
| 2010 | 14 | 4 | 18 |
| 2011 | 13 | 4 | 17 |
| 2012 | 13 | 5 | 18 |
| 2013 | 10 | 1 | 11 |
| 2014 | 13 | 1 | 14 |
| 2015 | 4 | 2 | 6 |
| 2016 | 6 | 4 | 10 |
| 2017 | 1 | 2 | 3 |
| 2018 | 6 | 2 | 8 |
| 2019 | 6 | 2 | 8 |
| 2020 | 4 | 1 | 5 |
| 2021 | 3 | 1 | 4 |
| 2022 | 5 | 0 | 5 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 1 | 2 |
Below are the most recent publications written about "HIV Protease Inhibitors" by people in Profiles.
-
Effects of Combination of Ethanol With Ritonavir, Lopinavir or Darunavir on Expression and Localization of the ER-Associated Set Protein and Infection of HIV-1 Pseudovirus in Primary Human Cells. J Acquir Immune Defic Syndr. 2024 06 01; 96(2):e6-e10.
-
Safety and Pharmacokinetics of Lopinavir/Ritonavir Oral Solution in Preterm and Term Infants Starting Before 3 Months of Age. Pediatr Infect Dis J. 2024 Apr 01; 43(4):355-360.
-
Molecular Factors and Pathways of Hepatotoxicity Associated with HIV/SARS-CoV-2 Protease Inhibitors. Int J Mol Sci. 2023 Apr 27; 24(9).
-
Antiretroviral protease inhibitors induce features of cellular senescence that are reversible upon drug removal. Aging Cell. 2023 01; 22(1):e13750.
-
Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients. Pharmacotherapy. 2023 07; 43(7):638-649.
-
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial. J Int AIDS Soc. 2022 06; 25(6):e25905.
-
Pharmacokinetics of Atazanavir Boosted With Cobicistat in Pregnant and Postpartum Women With HIV. J Acquir Immune Defic Syndr. 2022 03 01; 89(3):303-309.
-
Brief Report: No Differences Between Lopinavir/Ritonavir and Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy on Clearance of Plasmodium falciparum Subclinical Parasitemia in Adults Living With HIV Starting Treatment (A5297). J Acquir Immune Defic Syndr. 2022 02 01; 89(2):178-182.
-
Poorer Muscle Quality and Quantity With ART Initiation Is Associated With Greater Inflammation and Immune Activation. J Acquir Immune Defic Syndr. 2021 12 01; 88(4):399-405.
-
Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection. Clin Infect Dis. 2021 08 16; 73(4):706-715.